* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co OCF Margin % Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co OCF Margin % vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a OCF Margin % of -9.53% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #66 out of 118 companies in the Medical Distribution industry, placing it in the top 55.9%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's OCF Margin % too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current OCF Margin % is -9.53%. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #66 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's OCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #66 out of 118 companies for OCF Margin %. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. The industry median OCF Margin % is 2.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Distribution company?
The median OCF Margin % among Medical Distribution companies is 2.24, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median OCF Margin % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current OCF Margin % is -9.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.55 — trading 32.6% below its estimated fair value. The current OCF Margin % is -9.53%. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current OCF Margin % is -9.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.55 is trading 32.6% below its estimated GF Value™ of €2.30.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
OCF Margin %: -9.53%
GF Value™: €2.30 vs. price of €1.55 (32.6% below fair value)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
68GF Score
Get the complete analysis for FRA:GU5
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
